Unisec

Products

Universal flu vaccine concepts within the UNIFLUSECURE consortium:

M-001
9 conserved linear epitopes within the flu virus used to create a vaccine
Different phase II trial studies performed, phase IIb trial ongoing
BiondVax  Israel:
Link: http://www.biondvax.com/

FLU-V
Conserved epitopes within the flu virus used to create a synthetic peptide vaccine
Phase IIA trial studies performed, phase IIb trial initiated
SEEK (PepTcell Ltd) United Kingdom 
Link: http://www.seekacure.com/products/Flu_V.html

CTA1-3M2e-DD
A pandemic intranasal vaccine candidate based on the M2e conserved protein,with in-built DC-targeting and adjuvant properties
Pre-clinical
University of Goteborg, MIVAC Sweden
Link: http://www.ncbi.nlm.nih.gov/pubmed/18243429 

AAV NP /headless=HA-stalk
Recombinant Adeno-associated virus containing NP and headless HA stalk epitopes
Pre-clinical
Robert Koch Institute, Berlin, Germany
Link: http://www.rki.de/EN/Content/Institute/institute_node.html

Influenza A DNA vaccine
Needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. 6 different influenza proteins of pandemic origin.
Challenge studies with pigs ongoing.
Virus R&D Laboratory, Statens Serum Institut, Copenhagen, Denmark
Link: http://www.ncbi.nlm.nih.gov/pubmed/25746201 

CTA1-3M2e-DD
A pandemic intranasal vaccine candidate based on the M2e conserved protein,with in-built DC-targeting and adjuvant properties
Pre-clinical
University of Goteborg, MIVAC Sweden
Link: http://www.ncbi.nlm.nih.gov/pubmed/21481325

T-cell peptide vaccine
Reverse internal epitope selection: The scientific collaboration used a research method known as “Human Viral Challenge Studies”, where healthy volunteers are infected with influenza virus, and their immune responses closely monitored in an isolation unit. The selected peptides are being formulated into a T-cell peptide vaccine.
hVIVO Services Ltd (formerly Retroscreen Virology Ltd) United Kingdom
Link: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2612.html


Formulation and Application concepts developed by UNISEC

CAF01 Adjuvant
Immune profileCD4: Th1/Th17
Successfully through two Phase 1 clinical trials
Department of Infectious Disease Immunology, Statens Serum Institut Denmark
Link: http://www.ssi.dk

CAF09 Adjuvant
Immune profile CD8/CD4: Th1/Th17
Phase I clinical trial completed
Department of Infectious Disease Immunology, Statens Serum Institut Denmark
Link: http://www.ncbi.nlm.nih.gov/pubmed/24877765 

Pulmonary delivery
Adjuvants and formulations for whole inactivated influenza virus vaccines
Pulmonary delivery devices developed and tested for influenza vaccines.
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen
University Medical Center Groningen, The Netherlands
Link: http://www.sciencedirect.com/science/article/pii/S0939641115001708

IDAL delivery device
Intra Dermal Application of Liquids (IDAL) device (MSD animal health)
Needle-free intradermal application of a broadly protective influenza DNA vaccine for pigs.
Virus R&D Laboratory, Statens Serum Institut, Copenhagen, Denmark
Link: http://www.ncbi.nlm.nih.gov/pubmed/25746201 


Documents

pdf.png 1. FLU-v Universal Influenza Vaccine
Filename:
FLU-v Universal Flu Vaccine.pdf
Size:
320KB
Updated:
9/28/2015 9:55:27 AM
pdf.png 2. M-001 Universal Flu Vaccine
Filename:
M-001 Universal Flu Vaccine.pdf
Size:
2.5MB
Updated:
9/28/2015 9:57:11 AM